Reacción a "EMA recommends not to approve lecanemab against Alzheimer's disease"

The Phase III clinical trial of lecanemab showed that it does what it’s supposed to; it reduces toxic amyloid in the brain and slows cognitive decline. Scientifically, this was an important step forwards. However, the size of the effect was modest, and coupled with that there were significant side effects, including swelling and brain bleeds leading to death in a few people.

“The EMA’s decision will come as a disappointment to many, but there are reasons to remain hopeful. Lecanemab has shown that it is possible to slow down disease progression, and research does work. Now we need to ramp up our efforts to discover new and safer treatments. Scientists around the world are tackling this from different angles – from stopping toxic “tau” proteins moving through the brain, to protecting synapses, which allow neurons to communicate. Each discovery brings us closer to new and better treatments.